Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Marcucci

Showing results (331-340 of 536) with videos related to

Pageof 54
Sort By:
Blood Advances|July 15, 2022
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamideMonzr M Al Malki, Joycelynne Palmer, Ni-Chun Tsai, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Blood|June 29, 2012
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cellsYue Zhang, Xiaomei Yan, Goro Sashida, et al.
Journal of Hematology & Oncology|January 19, 2025
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effectsAda Alice Dona, Theophilus Tandoh, Lokesh Nigam, et al.
Blood|September 4, 2020
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALLYaqi Zhao, Ibrahim Aldoss, Chunxu Qu, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Leukemia|November 28, 2019
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALLSonia Rodriguez, Christina Abundis, Francesco Boccalatte, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Pageof 54

Showing results (331-340 of 536) with videos related to

Sort By:
Pageof 54
Blood Advances|July 15, 2022
Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamideMonzr M Al Malki, Joycelynne Palmer, Ni-Chun Tsai, et al.
Blood|April 2, 2008
High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) studyChristian Langer, Michael D Radmacher, Amy S Ruppert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 24, 2008
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B StudyGuido Marcucci, Kati Maharry, Michael D Radmacher, et al.
Leukemia & Lymphoma|September 12, 2022
Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML)Brian J Ball, Shukaib Arslan, Paul Koller, et al.
Blood|June 29, 2012
Stress hematopoiesis reveals abnormal control of self-renewal, lineage bias, and myeloid differentiation in Mll partial tandem duplication (Mll-PTD) hematopoietic stem/progenitor cellsYue Zhang, Xiaomei Yan, Goro Sashida, et al.
Journal of Hematology & Oncology|January 19, 2025
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effectsAda Alice Dona, Theophilus Tandoh, Lokesh Nigam, et al.
Blood|September 4, 2020
Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with B-ALLYaqi Zhao, Ibrahim Aldoss, Chunxu Qu, et al.
Blood|December 18, 2007
Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemiaShujun Liu, Zhongfa Liu, Zhiliang Xie, et al.
Leukemia|November 28, 2019
Therapeutic targeting of the E3 ubiquitin ligase SKP2 in T-ALLSonia Rodriguez, Christina Abundis, Francesco Boccalatte, et al.
Blood|January 6, 2018
Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myelomaEnrico Caserta, Junie Chea, Megan Minnix, et al.
Pageof 54